论文部分内容阅读
目的探讨小剂量尿激酶静脉溶栓治疗发病6 h内的脑梗死急性期的临床疗效。方法将入选患者80例随机分为溶栓组和对照组,每组各40例,分别进行临床疗效的全面观察。溶栓组选取发病不超过6 h,年龄在30~70岁,使用20万U尿激酶+生理盐水20m l静脉推注,续以尿激酶20~40万U加入生理盐水250 m l静脉点滴,每日1次,连用5~7 d。结果溶栓组疗效明显优于对照组,P<0.01差异有统计学意义。结论小剂量尿激酶超早期溶栓治疗能有效阻止血栓进展,减少再栓塞,有利于神经功能恢复,疗效显著而无明显副作用,比常规治疗起效快,作用强,致残率低且安全可靠,值得推广。
Objective To investigate the clinical efficacy of intravenous thrombolysis with low-dose urokinase in the acute stage of cerebral infarction within 6 hours of onset. Methods 80 patients were randomly divided into thrombolytic group and control group, 40 cases in each group, respectively, the clinical efficacy of a comprehensive observation. Thrombolytic group selected incidence of not more than 6 h, aged 30 to 70 years, the use of 20 million U of urokinase + saline 20m l intravenous injection, continued with urokinase 20 ~ 400 000 U 250 ml of normal saline intravenously, each Day 1, once every 5 to 7 days. Results The curative effect of thrombolytic group was better than that of control group, P <0.01 was statistically significant. Conclusion Ultra-early thrombolytic therapy with low-dose urokinase can effectively prevent thromboembolism, reduce re-embolization, facilitate the recovery of nerve function, and has obvious curative effect without obvious side effects. It has faster onset, stronger effect, lower morbidity and safety than conventional treatment , Worth promoting.